Clinical Trials Logo

Clinical Trial Summary

This is a Phase II single center, open-label, single arm study in patients with unresectable thymic epithelial tumors (Masaoka stage III, IVA). Patients will be treated with Pembrolizumab 200 mg, Docetaxel 75mg/m2, Cisplatin 75mg/m2 every 3 weeks for 3 cycles and will be evaluated for the operability. Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles. Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles. Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles. Otherwise patients are off the study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03858582
Study type Interventional
Source Samsung Medical Center
Contact Keunchil Park
Phone 82-2-3410-3459
Email keunchil.park@samsung.com
Status Recruiting
Phase Phase 2
Start date April 29, 2019
Completion date April 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05446935 - Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence N/A
Not yet recruiting NCT06200233 - Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor Phase 2
Not yet recruiting NCT03212027 - Preoperative Prediction of of Thymic Epithelial Tumors by Diffusion-Weighted MR Imaging N/A
Recruiting NCT04667793 - Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor Phase 2
Recruiting NCT02724696 - French National Observatory of Patients With Thymic Epithelial Tumor
Recruiting NCT05667948 - Molecular Analysis and Treatment Options of Thymic Malignancies
Recruiting NCT04522687 - Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer
Recruiting NCT06421805 - Establishing Prospective Mediastinal Tumor Database of PUMCH
Recruiting NCT04417660 - Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Phase 2
Not yet recruiting NCT04517539 - Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors Phase 2
Recruiting NCT06301945 - Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Recruiting NCT05104736 - PT-112 in Subjects With Thymoma and Thymic Carcinoma Phase 2
Recruiting NCT06311955 - Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor Phase 2